Study of Intravenous Immunoglobulin in Amnestic Mild Cognitive Impairment
Status:
Unknown status
Trial end date:
2019-12-01
Target enrollment:
Participant gender:
Summary
Patients with mild cognitive impairment (MCI) are a group recognized at being at high risk of
progressing to Alzheimer disease. Treatment of MCI with immunotherapy with intravenous
immunoglobulins (IVIG) could potentially reduce the risk of progression to Alzheimer disease.
This study will evaluate the efficacy of intravenous immunoglobulin in patients with MCI over
24 months after the first infusion. This study will also document conversion from MCI to
Alzheimer's Disease.